Oncogenic JAK2 V617F causes PD-L1 expression, mediating immune escape in myeloproliferative neoplasms-Reference-Cited by-同舟云学术

Oncogenic JAK2 V617F causes PD-L1 expression, mediating immune escape in myeloproliferative neoplasms

Published:2018-02-21 Issue:429 Volume:10 Page:
ISSN:1946-6234
Container-title:Science Translational Medicine
language:en
Short-container-title:Sci. Transl. Med.

Author:

Prestipino Alessandro¹²^ORCID,Emhardt Alica J.¹^ORCID,Aumann Konrad³^ORCID,O’Sullivan David⁴,Gorantla Sivahari P.¹,Duquesne Sandra¹,Melchinger Wolfgang¹,Braun Lukas¹^ORCID,Vuckovic Slavica⁵⁶^ORCID,Boerries Melanie⁷⁸⁹,Busch Hauke⁷¹⁰^ORCID,Halbach Sebastian⁷^ORCID,Pennisi Sandra¹²^ORCID,Poggio Teresa¹²^ORCID,Apostolova Petya¹¹¹,Veratti Pia¹⁸⁹,Hettich Michael¹²,Niedermann Gabriele¹²,Bartholomä Mark¹³^ORCID,Shoumariyeh Khalid¹^ORCID,Jutzi Jonas S.¹¹⁴^ORCID,Wehrle Julius¹⁸⁹¹¹^ORCID,Dierks Christine¹,Becker Heiko¹^ORCID,Schmitt-Graeff Annette³^ORCID,Follo Marie¹^ORCID,Pfeifer Dietmar¹^ORCID,Rohr Jan¹⁵^ORCID,Fuchs Sebastian¹⁵^ORCID,Ehl Stephan¹⁵,Hartl Frederike A.²¹⁶,Minguet Susana²¹⁵¹⁶^ORCID,Miething Cornelius¹⁸⁹^ORCID,Heidel Florian H.¹⁷¹⁸^ORCID,Kröger Nicolaus¹⁹^ORCID,Triviai Ioanna¹⁹^ORCID,Brummer Tilman⁷⁸⁹¹⁶^ORCID,Finke Jürgen¹,Illert Anna L.¹,Ruggiero Eliana²⁰,Bonini Chiara²⁰^ORCID,Duyster Justus¹⁸⁹,Pahl Heike L.¹^ORCID,Lane Steven W.⁵²¹²²^ORCID,Hill Geoffrey R.⁵²¹²²,Blazar Bruce R.²³^ORCID,von Bubnoff Nikolas¹⁸⁹^ORCID,Pearce Erika L.⁴^ORCID,Zeiser Robert¹⁸⁹¹⁶^ORCID

Affiliation:

1. Department of Hematology and Oncology, Medical Center, Faculty of Medicine, University of Freiburg, Freiburg 79106, Germany.

2. Faculty of Biology, Albert Ludwigs University of Freiburg, Freiburg 79104, Germany.

3. Institute of Surgical Pathology, Faculty of Medicine, University of Freiburg, Freiburg 79106, Germany.

4. Max Planck Institute for Immunobiology and Epigenetics, Freiburg 79108, Germany.

5. Department of Immunology, QIMR Berghofer Medical Research Institute, Brisbane, Queensland 4006, Australia.

6. School of Medicine, University of Queensland, Herston, Queensland 4006, Australia.

7. Institute of Molecular Medicine and Cell Research, Faculty of Medicine, University of Freiburg, Freiburg 79085, Germany.

8. German Cancer Consortium (DKTK) partner site Freiburg, Freiburg, Germany.

9. German Cancer Research Center (DKFZ), Heidelberg 69120, Germany.

10. Institute of Experimental Dermatology, Institute of Cardiogenetics, University of Lübeck, Lübeck 23562, Germany.

11. Berta-Ottenstein Programme, Faculty of Medicine, University of Freiburg, Freiburg 79106, Germany.

12. Department of Radiation Oncology, Faculty of Medicine, University of Freiburg, Freiburg 79106, Germany.

13. Department of Nuclear Medicine, Faculty of Medicine, University of Freiburg, Freiburg 79106, Germany.

14. Spemann Graduate School of Biology and Medicine, University of Freiburg, Freiburg 79085, Germany.

15. Center for Chronic Immunodeficiency, Medical Center, University of Freiburg, Freiburg 79106, Germany.

16. BIOSS Centre for Biological Signalling Studies, University of Freiburg, Freiburg 79104, Germany.

17. Internal Medicine II, Department of Hematology and Oncology, University Hospital of Jena, Jena 07745, Germany.

18. Leibniz Institute on Aging–Fritz Lipmann Institute, Jena 07745, Germany.

19. Department of Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf, Hamburg 20246, Germany.

20. Unit of Experimental Hematology, San Raffaele Scientific Institute, and University of Vita-Salute San Raffaele, Milano 20132, Italy.

21. Royal Brisbane and Women’s Hospital, Brisbane, Queensland, Australia.

22. University of Queensland, Herston, Queensland 4072, Australia.

23. Division of Blood and Marrow Transplantation, Department of Pediatrics, University of Minnesota, Minneapolis, MN 55455, USA.

Abstract

Oncogenic JAK mutation sensitizes myeloproliferative neoplasms to immune checkpoint inhibition.

Funder

European Research Council

Cancer Australia

Deutsche Forschungsgemeinschaft

Publisher

American Association for the Advancement of Science (AAAS)

Subject

General Medicine

Reference41 articles.

1. Interaction between B7-H1 and PD-1 determines initiation and reversal of T-cell anergy

2. PD-1 alters T-cell metabolic reprogramming by inhibiting glycolysis and promoting lipolysis and fatty acid oxidation

3. PD-L2 is a second ligand for PD-1 and inhibits T cell activation

4. Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade

5. MYC regulates the antitumor immune response through CD47 and PD-L1

Cited by 179 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Myeloid-derived suppressor cells: Implication in myeloid malignancies and immunotherapy;Acta Histochemica;2024-10

2. Programmed death‐ligand 1 expression in patients with primary or secondary myelofibrosis;Cancer Reports;2024-09

3. Chromosome 9p trisomy increases stem cells clonogenic potential and fosters T-cell exhaustion in JAK2-mutant myeloproliferative neoplasms;Leukemia;2024-08-23

4. Biomineralization-Tuned Nanounits Reprogram the Signal Transducer and Activator of Transcription 3 Signaling for Ferroptosis-Immunotherapy in Cancer Stem Cells;ACS Nano;2024-07-31

5. FRACTION: protocol of a phase II study of Fedratinib and Nivolumab combination in patients with myelofibrosis and resistance or suboptimal response to JAK-inhibitor treatment of the German MPN study group (GSG-MPN);Annals of Hematology;2024-07-05